Although the use of glitazones, such as rosiglitazone or pioglitazone, has been restricted due to moderate weight gain, peripheral fluid retention, and an increase in myocardial infarction risk (rosiglitazone), the non-thiazolidinedione, selective peroxisome proliferator-activated receptor-γ modulators, like INT131 besylate, could be promising candidates for randomized controlled trials with the potential to improve both glucose metabolism and NAFLD/NASH (while minimizing the side effects of full PPAR-γ agonists) [8, 42]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.